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Abstract
Background and Objectives
IVIg has been the preferred immunotherapy in stiﬀ-person syndrome (SPS) based on a
3-month controlled trial, but whether it is also eﬀective in inducing long-term beneﬁts or
arresting disease progression is unknown. The information is needed because SPS is a progressively disabling disease and IVIg is liberally used as chronic therapy without eﬃcacy data.
The present study explores the long-term eﬀects of IVIg in the largest cohort of wellcharacterized patients with SPS followed by the same clinicians over 10 years.
Methods
Data of 36 patients (32 glutamic acid decarboxylase [GAD] positive), diagnosed and treated
with monthly maintenance IVIg by the same neurologists, were analyzed. Response was
assessed by physician-observed changes, patients’ reports of symptom improvement, modiﬁed
Rankin Scale (mRS) scores, and dependency trials evaluating symptom recurrence after
stopping IVIg, prolonging infusion frequency, decreasing monthly dose, or wearing-oﬀ eﬀects
in between doses. Clinically meaningful long-term response was deﬁned by improved mRS
scores, improvement in physician-assessed stiﬀness, balance and gait, and functional decline
with dependency trials.
Results
Twenty-four of 36 (67%) patients had clinically meaningful response over a median 40-month
period. Patients with improved mRS scores by 1–2 points manifested improved gait, posture,
balance and decreased stiﬀness, spasms, and startle response; some patients using a wheelchair
and those ambulating with devices walked unassisted. In 25% of responders, treatment beneﬁt
was sustained for a 40-month median period, but in 29.1%, it declined over a 39-month period;
12.5% exhibited a conditioning eﬀect. Three of 5 patients with cerebellar GAD-SPS variant also
improved over time. The 12 patients who did not respond the ﬁrst 3 months remained
unresponsive even if IVIg continued for several months.
Discussion
This is a large study in 36 patients with SPS demonstrating that monthly maintenance IVIg
therapy oﬀers long-term beneﬁts in 67% of patients for a median 3.3-year period. Because
29.1% experienced diminishing beneﬁt over time due to disease progression, the study highlights the need for more eﬀective therapies.
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Glossary
GAD = glutamic acid decarboxylase; IVIg = intravenous immunoglobulin; mRS = modiﬁed Rankin Scale; SPS = stiﬀ-person
syndrome.

Stiﬀ-person syndrome (SPS) is an autoimmune disorder
characterized by simultaneous contraction of agonist and
antagonist muscles, resulting in muscle rigidity and
stiﬀness.1-5 Diagnostic criteria for SPS include stiﬀness of the
limbs and axial muscles, particularly abdominal and thoracolumbar paraspinals; superimposed painful spasms precipitated by emotional distress or unexpected tactile or
auditory stimuli; and high (>1: 10,000 by ELISA) serum
antiglutamic acid decarboxylase (GAD)-65 antibody titers in
up to 80% of the patients.1,4 Detailed follow-up data from 53
sequentially studied patients have shown that without immunotherapy, SPS is a progressive disease leading to cumulative physical disability over time even with the use of
antispasmodic medications such as baclofen, diazepam, and
gabapentin.6
Among the immunotherapeutic agents, high-dose intravenous immunoglobulin (IVIg) is currently the preferred treatment for patients with SPS who do not achieve
symptom control with muscle relaxants and benzodiazepines, based on a placebo-controlled randomized trial that
had shown that high-dose IVIg signiﬁcantly improves
stiﬀness, spasms, and gait, over a 3-month study period.7
Because SPS is a progressive disease, IVIg is currently used
as a chronic monthly treatment, although long-term eﬃcacy data are lacking. As a result, there is signiﬁcant overuse
while a placebo or conditioning eﬀect, common in onethird of patients receiving chronic IVIg therapy, is likely
overlooked.8,9
Considering that SPS is a rare disease, it is not practical to
perform a prospective long-term controlled study, while
giving placebo over long periods may raise clinical ethics
issues. Careful data collection in well-characterized patients followed by the same physicians using dependency
tests to distinguish true treatment beneﬁt from a conditioning or a placebo eﬀect, as previously witnessed in a
controlled study with rituximab,10 is a realistic option to
document long-term eﬃcacy. Apart from 2 small studies
with 2–5 patients over short time periods using subcutaneous immunoglobulin,11,12 there is only one relatively
large size study in 19 patients receiving IVIg13 that was
based on retrospective data collected using a patientreported scoring system without performing dependency
tests to objectively assess eﬃcacy.
The present study describes long-term data from the largest
cohort of patients with SPS treated monthly with IVIg and
followed over the last 10 years at a single academic center by
the same clinicians with expertise in SPS, including the
2

performance of 2 controlled trials,7,10 adhering to the same
clinical criteria. Importantly, this is also the ﬁrst study evaluating long-term IVIg beneﬁts trying to distinguish treatment
response from placebo or conditioning eﬀects by performing
IVIg dependency trials.8

Methods
All adults over the age of 18 with typical SPS,1 diagnosed by
the same neurologists based on the previously published diagnostic criteria1,2,7 and followed in our clinic within the last
10 years (2011–2021) were included in the study analysis. All
patients received IVIg as prescribed and monitored by the
same lead clinician and/or his trainees.
Data collected included demographic information, anti-GAD
Ab status, when symptoms started, duration and doses of
treatment with IVIg, patients’ subjective treatment response,
physician-observed eﬀects of IVIg, frequency of dependency
trials (or their equivalent), modiﬁed Rankin Scale (mRS)
scores, and estimated duration of meaningful beneﬁt from IVIg.
Response to IVIg was analyzed using both patients’ subjective
report of symptom improvement and physician assessments.
After initiation of IVIg, patients underwent dependency trials
when clinical improvement plateaued to conﬁrm continuing
need for therapy. A formal dependency trial was performed in
patients receiving IVIg by holding doses, prolonging the frequency of IVIg infusions to more than 4 weeks, or decreasing
the monthly IVIg dose to assess for recurrence of symptoms or
regression of symptom severity, as previously discussed.8 Other
equivalents to a formal dependency trial involved missed doses
due to insurance issues or the COVID-19 pandemic or observing a wearing-oﬀ eﬀect in between IVIg doses. Of importance, the subgroup analysis was precisely performed to
distinguish the patients who did not undergo dependency trials
from those who did. A modiﬁed Rankin Scale score was calculated based on documentation before starting IVIg, after the
ﬁrst few months of full IVIg dose, and at follow up visits while
on maintenance therapy to evaluate for functional improvement. A clinically meaningful response to IVIg was deﬁned by a
change in the mRS score after IVIg treatment; improvement in
physician-assessed stiﬀness, balance, and gait; or a decline in
stiﬀness, balance, gait, and daily functioning with dependency
trials. Duration of meaningful beneﬁt was calculated based on
patient and physician assessment of when treatment with IVIg
no longer produced clinically meaningful changes.
IVIg dosing was also taken into consideration based on the
information available in the records. Every patient was generally treated ﬁrst with an IVIg dose of 2 g/kg of body weight
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Table 1 Characteristics of Patients With SPS Who Responded to Long-term IVIg Maintenance Therapy (IVIg Responders)
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Age/sex

Time from
symptom onset to
diagnosis (y)

Time from symptom
onset to treatment
with IVIg (y)

GAD
antibody
positivity

Dependency trials

Total
duration of
IVIg (mo)

Estimated
duration of clinical
benefit (mo)
IVIg benefit

Type of responder

R1

55/F

9

11

GAD Ab (+)

Continued benefit

Wearing-off effect

38

38

Decreased spasms and improved gait

R2

41/F

0

0

GAD Ab (+)

Continued benefit

Wearing-off effect

42

42

Decreased spasms and improved gait
(mRS score 4 → 2)

R3

32/F

14

Cannot determine

GAD Ab (+)

Continued benefit

Wearing-off effect

At least 55

At least 55

Decreased spasms

R4

49/F

1

1

GAD Ab (+)

Continued benefit

None, recently started IVIg

13

13

Decreased stiffness and back pain;
improved gait (mRS score 3 → 2)

R5

54/F

2

4

GAD Ab (+)

Continued benefit

None

At least 28

At least 28

Improved function and gait (mRS score
4 → 3)

R6

78/F

11

14

GAD Ab (+)

Continued benefit

Wearing-off effect

62

62

Unspecified

R7

47/F

3

3

GAD Ab (+)

Decreasing benefit

Wearing-off effect; decreased
frequency

41

19

Improved walking, stiffness, flexibility,
facial expression, and dysarthria

R8

59/F

Cannot determine

Cannot determine

GAD Ab (+)

Decreasing benefit

Wearing-off effect

At least 16

Cannot determine

Unspecified

R9

40/F

7

8

GAD Ab (-)

Decreasing benefit

Wearing-off; decreased
frequency and dose

22

22

Increased energy; decreased pain and
spasms; improved gait

R10 72/F

26

26

GAD Ab (+)

Decreasing benefit

Missed dose due to COVID

63

50

Improved gait and balance; decreased
spasms; decreased pain (mRS score
3 → 2)

R11 53/M

1

1

GAD Ab (+)

Decreasing benefit

6-mo gap without insurance

31

31

Improved gait and walking speed and
faster speech (mRS score 4 → 3)

R12 57/F

1

1

GAD Ab (+)

Decreasing benefit

Decreased frequency during
COVID

121

Cannot determine

Improved pain, stiffness, and gait

R13 59/M

1

2

GAD Ab (+)

Decreasing benefit

Wearing-off effect; dose held

39

39

Improved balance and gait; decreased
rotary nystagmus and rigidity

R14 60/F

6

8

GAD Ab (+)

No dependency trial

None

At least 58

Cannot determine

Decreased stiffness and spasms

R15 73
4
(now
deceased)/F

0

GAD Ab (+)

No dependency trial

None

143

Cannot determine

Unspecified

R16 56/F

2

4

GAD Ab (+)

No dependency trial

None

90

Cannot determine

Improved gait; decreased stiffness and
spasms (mRS score 4 → 2)

R17 51/F

7

8

GAD Ab (+)

No dependency trial

None

At least 23

Cannot determine

Improved gait, decreased stiffness

ID
#

Continued

3

4
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Table 1 Characteristics of Patients With SPS Who Responded to Long-term IVIg Maintenance Therapy (IVIg Responders) (continued)
Time from
symptom onset to
diagnosis (y)

Time from symptom
onset to treatment
with IVIg (y)

GAD
antibody
positivity

Dependency trials

Total
duration of
IVIg (mo)

Estimated
duration of clinical
benefit (mo)
IVIg benefit

Type of responder

R18 57/F

0

0

GAD Ab (+)

No dependency trial

None

13

Cannot determine

Decreased stiffness

R19 74/F

1

1

GAD Ab (+)

Conditioning effect

Dose held; dose decreased

58

54

Improved gait and mobility; decreased
stiffness and pain (mRS score 4 → 3)

R20 60/M

Cannot determine

Cannot determine

GAD Ab (+)

Conditioning effect

Doses held for 6 mo after PE; dose 23
held; wearing-off effect

20

Decreased spasms and stiffness;
decreased startle response

R21 62/F

Cannot determine

Cannot determine

GAD Ab (+)

Conditioning effect

Wearing-off effect; decreased
frequency due to insurance;
decreased dose

216

205

Improved mobility; decreased spasms
and stiffness

R22 72/F

3

3

GAD Ab (+)

Discontinued
prematurely

N/A

48

N/A

Improved gait; decreased spasms and
stiffness

R23 68/F

5

8

GAD Ab (-)

Decreasing benefit over
time; discontinued
prematurely

Wearing-off effect; dose held

12

N/A

Improved balance, walking speed, and
posture; decreased startle response
and spasms

R24 61/F

0

1

GAD Ab (+)

Discontinued
prematurely

Dose held

11

N/A

Improved gait; decreased stiffness
(mRS score 4 → 3)

ID
#

Age/sex

Abbreviations: IVIg = intravenous immunoglobulin; mRS= modified Rankin Scale; N/A = not applicable; SPS = stiff-person syndrome.
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Figure 1 Median Duration and Range of IVIg Treatment in 36 Patients With Stiff-Person Syndrome Categorized as IVIg
Responders or Nonresponders

IVIg responders were subcategorized based on their response to long-term treatment—continued benefit over time, decreasing benefit over time, demonstration of a conditioning effect, not assessed with a dependency trial, or unable to assess due to premature discontinuation of therapy.

for at least 3 months, as in our original IVIg trial.7 The subsequent maintenance IVIg doses either remained the same
(2 g/kg per month) throughout the follow-up period or varied
from 1 to 2 g/kg every 3–6 weeks based on the results of
dependency tests, as per standard IVIg maintenance protocol
for all neurologic disorders.8
Data Availability
Data not provided in the article due to space limitations may
be shared (anonymized) at the request of any qualiﬁed investigator for purposes of replicating the results.
Standard Protocol Approvals, Registrations,
and Patient Consents
Chart review and data analysis were approved by the IRB of
the Jeﬀerson Oﬃce of Human Research (MCD: principal
investigator). Patient consent was not required for this retrospective chart review.

Results
Demographics
The study included 36 patients, 29 women and 7 men, of
median age 58 years (range 32–81 years). Time from
symptom onset to SPS diagnosis ranged from 0 years
(diagnosed the same year as symptom onset) to 26 years,
with a median of 3.5 years. Time from symptom onset to
treatment with IVIg ranged from 0 years (treated the same
year as symptom onset) to 26 years with a median of 4
years. Thirty-two of the 36 patients were positive for GAD65 antibodies with high titers, as previously
speciﬁed1,4,14-16; 4 patients were diagnosed with seronegative SPS based on all the other required criteria and
exclusions4,5 (Table 1, eTable 1, links.lww.com/NXI/
A732). Five GAD-positive patients also had cerebellar
involvement, as part of GAD-SPS spectrum disorder.4,5,17
Neurology.org/NN

Overall Clinical Changes and Benefits From IVIg
Of the 36 patients, 24 (67%) had a clinically signiﬁcant response to treatment with IVIg, similar to what was noted in
our original short-term (3-month) controlled study,7 with
beneﬁt extended up to a median period of 40 months
(Figure 1). Of the 4 patients with seronegative SPS, 2 improved with IVIg; 1 had complications and discontinued
treatment after a single dose, and the fourth did not respond
to IVIg. Subjectively, the responders reported the following
overall long-term experience with IVIg: improved gait, improved daily functioning, improved balance, decreased dysarthria and faster speech, decreased stiﬀness, decreased
painful spasms, improved energy, decreased startle response,
improved posture, and improved facial expression (Table 1).
Based on objective neurologic examinations, responders were
noted to have decreased rigidity, improved gait, improved
facial expression, decreased nystagmus, and decreased dysarthria (in the patients with SPS and cerebellar ﬁndings).
Among the 36 patients who received IVIg, 12 patients did not
exhibit any beneﬁt (as deﬁned above), at any time during a
median of 3 months (range 1–24 months) of IVIg treatment
(Figure 1; eTable 1, links.lww.com/NXI/A732). No diﬀerences in the clinical phenotype, GAD Ab status, or symptomatology characteristics were noted between the responders and
nonresponders.
Response Assessed by the Modified Rankin
Scale Score
Of the 24 IVIg responders, 8 patients (33%) responded to the
extent that their modiﬁed Rankin Scale score improved by 1
point (in 6 patients) or by 2 points (in 2 patients), most
dramatically illustrated by the ability to walk without an
assistive device after treatment. Speciﬁcally, 6 of these patients
were using a wheelchair before starting IVIg but became able
to walk independently (R2 and R16; Table 1) or with a cane
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Figure 2 Relative Proportion of Patients With Stiff-Person Syndrome Who Responded to IVIg Therapy in Each Subcategory
of Responders With the Median Duration and Range of Treatment for Each Category

or walker (R5, R11, R19, and R24; Table 1) several months
after IVIg; 2 others who required a cane or a walker to walk
pre-IVIg became able to walk without assistance after several
IVIg courses (R4, R10; Table 1). The other 16 responders
maintained the same mRS score after long-term IVIg treatments, demonstrating a stabilizing eﬀect.
Duration of Long-term Benefit of IVIg and
Dependency Tests
For the 24 IVIg responders, the duration of treatment ranged
from 11 to 216 months, with a median of 40 months (Figure 1).
Sixteen of the 24 responders underwent formal dependency trials
or an equivalent. After holding their IVIg infusions, reducing the
monthly IVIg dose from 2 g/kg to 1 g/kg or prolonging the
frequency of the infusions, there was a clear symptom recurrence
indicating that maintenance therapy was beneﬁcial and still
needed. One patient (R1; Table 1) who declined further when
IVIg was held due to poor venous access exhibited a satisfactory
clinical response with less side eﬀects when switched to SCIg; in
this patient, SCIg continues to ensure improvement and stability
for the last 2 years. Eight of the 24 responders continued receiving treatment without undergoing a formal dependency test
(Figure 2); 2 of these patients continued to experience clear
beneﬁt and were categorized in Table 1 in the responders with
continued beneﬁt subgroup; another prematurely discontinued
therapy because of medical comorbidities and was categorized in
Table 1 in the discontinued prematurely subgroup; the remaining 5 continued on IVIg for a median of 58 months (range
13–143 months) because it was felt to be beneﬁcial and were
categorized in Table 1 in the responders with no dependency
trial subgroup.
Subgroup Analysis of Long-term Responders
Based on Continuing Stability, Declined
Benefit, Conditioning Effect, or Safety Issues
Of the 24 patients who beneﬁted from IVIg with a high
maintenance dose of 2 g/kg per month, 6 patients (25%) with
active disease continued to experience and exhibit clinically
6

meaningful beneﬁt for a median duration of 40 months (range
13–62 months) (Figure 1). Seven other patients (29.1%) also
exhibited clinically meaningful improvement based on dependency trials for a median of 39 months (range 16–121
months), but started to notice a decreasing relative treatment
beneﬁt after an estimated median of 31 months (range 19–50
months), despite receiving high-dose IVIg treatments
(Figure 2 and Table 1).
Three of the 24 responders (12.5%) (Figure 2) who initially
demonstrated clear beneﬁt experienced decreasing beneﬁt over
time but were continued on maintenance therapy despite a lack
of objective decline with dependency tests. These patients
requested continuation of IVIg therapy, citing increased fatigue
and pain without treatment and expressing fear that their
functional status would decline if not continued on maintenance therapy, exhibiting a form of conditioning eﬀect.8,9 This
patient subgroup remained on maintenance therapy for a median duration of 58 months (range 23–216 months) (Figure 2).
Of the 24 patients who beneﬁted from IVIg, 3 patients (12.5%)
prematurely discontinued treatment after a median period of
12 months (range 11–48 months) due to other medical
comorbidities (Figures 1 and 2). One patient discontinued
IVIg due to cardiac risk factors, another due to starting other
immunotherapies for rheumatologic conditions, and the third
as advised due to a prior intracerebral hemorrhage considered
unrelated to IVIg. Overall, other than the common and mild
infusion–related reactions,8 no major adverse events were observed with the chronic IVIg treatments.
GAD-Positive Patients With SPS With Cerebellar
Involvement (GAD-SPS Spectrum)
Five GAD-positive patients with SPS also had cerebellar
ﬁndings with ataxia and dysarthria, consistent with GADSD.4,5,10 Three of these patients (R7, R11, and R13; Table 1)
exhibited a beneﬁcial response to IVIg with objective improvement in speech, balance, and nystagmus but with
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decreasing beneﬁt over time. One patient (R11, Table 1) had
a substantial response with improvement in the mRS score,
going from being a wheelchair user before IVIg to being able
to walk with a walker after IVIg; he gradually exhibited,
however, decreasing beneﬁt and switched to rituximab. Two
other patients (NR3 and NR8; eTable 1, links.lww.com/NXI/
A732) did not show convincing signs of improvement and
were categorized as nonresponders, although 1 patient noted
a mild but transient improvement in gait.

Discussion
The study demonstrates that maintenance therapy with IVIg
continues to be eﬀective over a median of 3.3 years in 67% of
patients with typical SPS, improving daily functioning, gait, balance, painful spasms, posture, and facial expression with a demonstrable eﬀect in decreasing stiﬀness, spasms and startle
response. Although uncontrolled due to disease rarity and clinical
ethics to give placebo over 2–3 years, this is a long-term study in a
large group of patients with SPS seen over time by the same
experienced clinicians that documents continued IVIg eﬃcacy
based on a combination of mRS scores, dependency tests, and
objective clinical observations. The results complement the conclusions from the original short-term 3-month controlled study
that the same investigators conducted 20 years ago with a much
smaller number of enrolled patients.7 The present analysis,
however, highlights several additional observations of increased
clinical and practical importance.
First, 33% of responders experienced improvement in their main
disabling symptoms over time substantial enough to improve
their mRS score by 1 or 2 points; patients who were using a
wheelchair or unable to ambulate independently before receiving
IVIg became able to walk with an assistive device or independently with maintenance therapy. This demonstrates that a
subset of patients can achieve and maintain major functional
improvement with monthly IVIg. Given that in a longitudinal
study patients with SPS manifested disabling progression over a
2–4-year observational period,6 the present data show that
maintenance IVIg therapy provides a stabilizing eﬀect and may
delay disease progression.
Second, among all IVIg responders, 25% continued to experience
persistent beneﬁt for a median period of 40 months (range 13–62
months); 29.1% of them, however, started to experience diminishing relative beneﬁt after an estimated median period of 31
months. Such a declining eﬃcacy was not related to prolonged
infusion frequency or reduced IVIg dosing, given that patients
continued on a high dose of 2 g/kg per month as determined by
the dependency tests, but it rather represents reduced eﬀect most
likely due to disease progression. As stated earlier, the longitudinal
study with 57 GAD-positive patients with SPS examined and followed at the NIH every 6 months for a 2-year period by the same
clinicians as in this study had shown that SPS is a progressive
disease; 80% lost the ability to walk independently after a 2-year
follow-up period without immunotherapy, exhibiting increased
stiﬀness and heightened sensitivity scores, worsening functional
Neurology.org/NN

status, higher frequency of falls, and impaired ability to walk independently or perform work duties.6 Importantly, after the ﬁrst
two-year follow up period, 5 patients could no longer function with
only antispasmodic therapy and required intermittent IVIg infusions with considerable beneﬁt.6 On this basis, the present study
suggests that IVIg may inhibit disability progression for a period of
time in a considerable subset of patients with SPS, but the observation that 33% of patients did not respond and that 29.1%
exhibited decreasing beneﬁt over time highlights the need for more
eﬀective maintenance therapies, especially at the time when the
beneﬁt of IVIg starts to decline.
Third, a small (12.5%) patient subset with demonstrable initial
improvement felt the need to continue on maintenance IVIg for a
median of 58-month observational period, despite acknowledging
no signiﬁcant objective diﬀerence with dependency tests. These
patients asserted that IVIg was helpful in reducing fatigue and pain,
while expressing fear that they would decline if not continued on
maintenance therapy. Such a conditioning eﬀect, initially observed
in patients with CIDP receiving maintenance IVIg therapy,9 has
now been observed in patients with other autoimmune neurologic
conditions on chronic IVIg therapy.8 In the 2 large controlled
CIDP trials, ICE and PATH, 37% of patients randomized to placebo remained stable for a 24-week study period, even if they were
previously observed to be IVIg-dependent.8,9 Because a placebo
eﬀect has been also noted in our randomized trial on patients with
SPS receiving rituximab,10 a placebo component cannot be excluded among the small number of those patients in the present
study who exhibited beneﬁt but did not undergo dependency trials.
Carefully performing periodic dependency trials in patients with
SPS receiving chronic IVIg therapy remains fundamental to avoid
overuse; furthermore, educating patients from the outset of potential risks is essential, especially in poorly mobilized patients with
SPS with other comorbidities, such as insulin-dependent diabetes
who are at risk for thrombosis and other adverse eﬀects.8 The
observation that 33% of patients who did not respond to IVIg
during the ﬁrst 3 months did not also respond even when therapy
continued for up to 20 months underscores the need for prudent
use of IVIg in clinical practice to avoid overuse.
Fourth, long-term high-dose IVIg tolerance was very good
with only 3 of the 24 responders discontinuing therapy prematurely due to IVIg-related side eﬀects or other medical
comorbidities. Two of the nonresponders also had IVIg-related
side eﬀects or medical comorbidities preventing continued use.
Despite some study limitations, mainly the lack of a control
group due to obvious diﬃculties in giving placebo for long
periods in a rare disease and the constraints of a retrospective
chart review, this study has conclusively demonstrated the effectiveness of IVIg as chronic maintenance therapy while
highlighting the need for new or novel therapies for the chronic
management of SPS. Promising immunotherapies should be,
however, tested in a randomized controlled design, as done
with the rituximab trial,10 but in a larger number of patients
involving many centers, or as concluded from the results of the
large but uncontrolled hematopoietic stem cell transplantation
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study that led to early termination.18,19 Although both of these
studies failed to show eﬃcacy, rituximab and autologous hematopoietic stem cell transplantation can still provide beneﬁt in
some patients with SPS over a long time period.10,20,21
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